Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Chang, G., & Roth, C. B. (2001) · Science · doi:10.1126/science.293.5536.1793 · Cited by 619
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
BackgroundSelf-citationABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“The ABC transporter family ABC transporters, named after their distinctive ATP-binding cassette domains, are conserved proteins that typically translocate solutes across cellular membrane”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drug-resistant tumour relaps”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Items 401–500 of 1,013
Disulfide based prodrugs for cancer therapy
Wang, Q., Guan, J., Wan, J., & Li, Z. (2020) · RSC Advances · doi:10.1039/d0ra04155f · Cited by 132
Payton, M. N., Bush, T. L., Chung, G., Ziegler, B., Eden, P., McElroy, P. L., Ross, S. L., Cee, V. J., Deak, H. L., Hodous, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3001 · Cited by 128
“Inhibition of P-gp and BCRP drug pumps with GF120918 (21) sensitized HCT-15 and RPMI-8226 cells to AZD1152, suggesting that the loss of potency in the MDR cell lines was due to drug efflux (data not shown).”
TrAp: a tree approach for fingerprinting subclonal tumor composition
Strino, F., Parisi, F., Micsinai, M., & Kluger, Y. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt641 · Cited by 139
Henderson, M. J., Haber, M., Porro, A., Munoz, M. A., Iraci, N., Xue, C., Murray, J., Flemming, C. L., Smith, J., Fletcher, J. I., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr256 · Cited by 124
“103, Issue 16 | August 17, 2011 endogenous substrates that are capable of influencing tumor behavior [reviewed in (11,31,32)].”
Integration of phytochemicals and phytotherapy into cancer precision medicine
Efferth, T., Saeed, M. E. M., Mirghani, E., Alim, A., Yassin, Z., Saeed, E. M., Khalid, H. E., & Daak, S. (2017) · Oncotarget · doi:10.18632/oncotarget.17466 · Cited by 143
Writers, readers, and erasers RNA modifications and drug resistance in cancer
Chen, D., Gu, X., Nurzat, Y., Xu, L., Li, X., Wu, L., Jiao, H., Gao, P., Zhu, X., Yan, D., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02089-6 · Cited by 148
Caveolin-1: A tumor-promoting role in human cancer
Shatz, M., & Liscovitch, M. (2008) · International Journal of Radiation Biology · doi:10.1080/09553000701745293 · Cited by 125
“…(P-gp) and multidrug resistance-related protein 1 (MRP1); changes in structural properties of the plasma membrane (viscosity, permeability) that alter cellular drug pharmacokinetics; and modifications in path- ways leading to apoptosis and/or growth arrest upon drug exposure (Szakacs et al. 2006).”
BackgroundChen, X., Li, Y., Li, S., Gao, M., Ren, L., & Tang, B. Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201804362 · Cited by 123
Jabeen, I., Pleban, K., Rinner, U., Chiba, P., & Ecker, G. F. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201705f · Cited by 135
Tang, S., Yin, Q., Zhang, Z., Gu, W., Chen, L., Yu, H., Huang, Y., Chen, X., Xu, M., & Li, Y. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.04.025 · Cited by 126
“Multidrug resistance (MDR) is one of the main obstacles to the successful chemotherapy of breast cancer because MDR could result in increase of drug efflux, activation of the detoxification system, DNA repair and blockage of apoptosis, etc [1,2].”
BackgroundWang, S., Yang, L., Cho, H.-Y., Dean Chueng, S.-T., Zhang, H., Zhang, Q., & Lee, K.-B. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119498 · Cited by 125
“thereby increase drug accumulation, cell apoptosis and partially overcome the chemoresistance [62,63].”
BackgroundABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome
Elliott, A. M., & Al‐Hajj, M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0235 · Cited by 127
“ABCB8-Mediated Chemoresistance in Melanoma Cells Is Specific to Doxorubicin A common feature of ABC transporters is their ability to confer cross-resistance to a variety of structurally unrelated drugs (2).”
BackgroundThe pharmacology of cancer resistance.
O'Connor, R. A. (2007) · PubMed · Cited by 123
Gou, Y., Li, J., Fan, B., Xu, B., Zhou, M., & Yang, F. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.026 · Cited by 129
Zhang, D., Hop, C. E. C. A., Patilea-Vrana, G., Gampa, G., Seneviratne, H. K., Unadkat, J. D., Kenny, J. R., Nagapudi, K., Di, L., Zhou, L., et al. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086744 · Cited by 130
“secondary barrier to drug delivery to tumors in the brain (Demeule et al., 2001; Dean et al., 2005; Szakacs et al., 2006; Fattori et al., 2007; Luo et al., 2012).”
BackgroundMeijerman, I., Beijnen, J. H., & Schellens, J. H. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.002 · Cited by 132
Investigational ABC transporter inhibitors
Falasca, M., & Linton, K. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679339 · Cited by 120
“Other members of the human ABC transporter family have been found overexpressed in several different cancer types [6-8].”
BackgroundIn vitro effect of quercetin on human gastric carcinoma: Targeting cancer cells death and MDR
Borska, S., Chmielewska, M., Wysocka, T., Drąg‐Zalesińska, M., Zabel, M., & Dzięgiel, P. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.06.035 · Cited by 122
Efficacy of traditional Chinese medicine in treating cancer
Nie, J., Zhao, C., Deng, L., Chen, J., Yu, B., Wu, X., Pang, P., & Chen, X. (2015) · Biomedical Reports · doi:10.3892/br.2015.537 · Cited by 120
“…of cytotoxic drugs to kill cells, such as alterations in cell cycle, increased repair of DNA damage, reduced apoptosis and altered metabolism of drugs; and iii) increased energy‑dependent efflux of hydrophobic drugs that can easily enter the cells by diffusion through the plasma membrane (25).”
Karthikeyan, S., & Hoti, S. (2015) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150113103439 · Cited by 111
“to a wide array of anti-cancer agents [27].”
BackgroundWang, S., Kim, G., Lee, Y.-E. K., Hah, H. J., Ethirajan, M., Pandey, R. K., & Kopelman, R. (2012) · ACS Nano · doi:10.1021/nn301633m · Cited by 134
“their absorption, metabolism, and delivery to target tissues.(5) Thus, there is a clear need”
The role of photodynamic therapy on multidrug resistant breast cancer
Aniogo, E. C., George, B. P. A., & Abrahamse, H. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0815-0 · Cited by 127
Chekhun, V. F., Lukianova, N. Y., Kovalchuk, O., Tryndyak, V., & Pogribny, I. P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0663 · Cited by 131
“The development of cancer cells that are resistant to chemotherapeutic agents is a major clinical obstacle to the successful treatment of cancer, including breast cancer (1, 2).”
BackgroundBrózik, A., Hegedüs, C., Erdei, Z., Hegedűs, T., Özvegy‐Laczka, C., Szakács, G., & Sarkadi, B. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.562892 · Cited by 128
“Until now, at least 12 of the 48 human ABC proteins have been documented to contribute to the emergence of in vitro MDR [2,10,11].”
BackgroundInfluentialSelf-citationABC proteins in antigen translocation and viral inhibition.
Parcej, D., & Tampé, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.410 · Cited by 124
“This resembles the situation of multidrug exporters, which are able to transport, selectively, a wide range of drug”
BackgroundNew approaches for understanding mechanisms of drug resistance in schistosomes
Greenberg, R. M. (2013) · Parasitology · doi:10.1017/s0031182013000231 · Cited by 122
“In addition to Pgp, known ABC proteins involved in MDR include the multidrug resistance-associated proteins (MRPs; ABCCs), breast cancer resistance protein (BCRP; ABCG2), as well as others (Szakacs et al. 2006).”
InfluentialRecent progress in macrocyclic amphiphiles and macrocyclic host-based supra-amphiphiles
Zhu, H., Shangguan, L., Shi, B., Yu, G., & Huang, F. (2018) · Materials Chemistry Frontiers · doi:10.1039/c8qm00314a · Cited by 124
Abouzeid, A. H., Patel, N. R., & Torchilin, V. P. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.01.009 · Cited by 118
The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters
Planas, J. M., Alfaras, I., Colom, H., & Juan, M. E. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.06.004 · Cited by 138
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
Bagnyukova, T. V., Serebriiskii, I. G., Zhou, Y., Hopper-Borge, E. A., Golemis, E. A., & Astsaturov, I. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.9.13738 · Cited by 118
Tong, X.-Z., Wang, F., Liang, S.-L., Zhang, X., He, J., Chen, X.-G., Liang, Y.-J., Mi, Y., To, K. K. W., & Fu, L. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.007 · Cited by 126
New Ruthenium(II)–Letrozole Complexes as Anticancer Therapeutics
Castonguay, A., Doucet, C., Juhas, M., & Maysinger, D. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301103y · Cited by 118
How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient
Hansen, E., Woods, R. J., & Read, A. F. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2001110 · Cited by 124
Zhou, Y. M., Wang, Y., Zhou, W., Chen, T., Wu, Q., Chutturghoon, V. K., Lin, B., Geng, L., Yang, Z., Zhou, L., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0898-7 · Cited by 129
Zhu, L., Guo, Y., Qian, Q., Yan, D., Li, Y., Zhu, X., & Zhang, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006895 · Cited by 122
β-Carbolines as potential anticancer agents
Aaghaz, S., Sharma, K., Jain, R., & Kamal, Ä. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113321 · Cited by 116
Xuan, Y., & Hu, X. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.029 · Cited by 123
“In vitro, these three transporters efflux a broad range of chemotherapeutic agents used clinically for first- and second-line treatment of cancer [8].”
BackgroundZhong, Y., Wang, C., Cheng, L., Meng, F., Zhong, Z., & Liu, Z. (2013) · Biomacromolecules · doi:10.1021/bm400530d · Cited by 119
Ke, C., Chiang, W., Liao, Z.-X., Chen, H., Lai, P., Sun, J., & Sung, H. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.023 · Cited by 121
Chufan, E. E., Kapoor, K., Sim, H.-M., Singh, S., Talele, T. T., Durell, S. R., & Ambudkar, S. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082463 · Cited by 116
“Pgp is known to recognize and transport a variety of chemically dissimilar compounds including amphipathic anticancer agents [1–3].”
BackgroundMathematical modeling as a tool for planning anticancer therapy
Świerniak, A., Kimmel, M., & Śmieja, J. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.041 · Cited by 120
“More specifically, three major mechanisms contributing to drug resistance have been identified (Szakacs et al., 2006, Takemura et al., 1997): 1.”
BackgroundInduction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR
Tsang, W. P., Wong, T. W. L., Cheung, H., Co, C., & Kwok, T. T. (2007) · RNA · doi:10.1261/rna.359007 · Cited by 120
How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
Jaramillo, A. C., Saig, F. A., Cloos, J. J., Jansen, G., & Peters, G. J. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.02 · Cited by 124
“derivatives increases inhibition AML/high-risk MDS [26,98-112]”
Surfactant–Polymer Nanoparticles Overcome P-Glycoprotein-Mediated Drug Efflux
Chavanpatil, M. D., Khdair, A., Gérard, B., Bachmeier, C. J., Miller, D. W., Shekhar, M. P. V., & Panyam, J. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070024d · Cited by 117
Burkhart, C. A., Watt, F., Murray, J., Pajic, M., Prokvolit, A., Xue, C., Flemming, C., Smith, J., Purmal, A., Isachenko, N., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1075 · Cited by 117
“Past attempts at modulating multidrug resistance have failed mainly due to nonspecific side effects that became apparent when modulators were combined with conventional drugs (22).”
BackgroundBram, E. E., Stark, M., Raz, S., & Assaraf, Y. G. (2009) · Neoplasia · doi:10.1593/neo.91314 · Cited by 117
Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors
Klepsch, F., Vasanthanathan, P., & Ecker, G. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400289j · Cited by 101
Combination of chemotherapy and photodynamic therapy for cancer treatment with sonoporation effects
Lee, H., Han, J., Shin, H., Han, H., Na, K., & Kim, H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.008 · Cited by 123
Chemotherapy Resistance Explained through Endoplasmic Reticulum Stress-Dependent Signaling
Bahar, E., Kim, J., & Yoon, H. (2019) · Cancers · doi:10.3390/cancers11030338 · Cited by 122
“As an example, the over-expression of ABC transporters on the plasma membrane can promote drug resistance in cancer cells [61].”
BackgroundWang, N., Wang, Z., Peng, C. Y., You, J., Shen, J., Han, S., & Chen, J. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu187 · Cited by 116
Regulation of miR-19 to Breast Cancer Chemoresistance Through Targeting PTEN
Liang, Z., Li, Y., Huang, K., Wagar, N., & Shim, H. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0570-y · Cited by 124
“Nearly all initially responsive breast tumors will eventually acquire an MDR phenotype (2).”
BackgroundChemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway
Singh, S., Chitkara, D., Mehrazin, R., Behrman, S. W., Wake, R. W., & Mahato, R. I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040021 · Cited by 115
“Many prostate cancers relapse due to the presence of highly chemoresistant tumor initiating/cancer stem cells [7,8].”
BackgroundTan, K. W., Li, Y., Paxton, J. W., Birch, N. P., & Scheepens, A. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.12.021 · Cited by 128
Chen, C.-K., Law, W.-C., Aalinkeel, R., Yu, Y., Nair, B., Wu, J., Mahajan, S., Reynolds, J. L., Li, Y., Lai, C. K., et al. (2014) · Nanoscale · doi:10.1039/c3nr04804g · Cited by 116
Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent
Wen, L., Liang, C., Chen, E., Chen, W., Liang, F., Zhi, X., Wei, T., Xue, F., Li, G., Yang, Q., et al. (2016) · Scientific Reports · doi:10.1038/srep23269 · Cited by 115
Mei, L., Zhu, G., Qiu, L., Wu, C. S., Chen, H., Liang, H., Cansız, S., Lv, Y., Zhang, X., & Tan, W. (2015) · Nano Research · doi:10.1007/s12274-015-0841-8 · Cited by 118
Cancer Stem Cells: Cellular Plasticity, Niche, and its Clinical Relevance
Lee, G., Hall, R. R., & Ahmed, A. U. (2016) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.1000363 · Cited by 129
“Enhanced therapeutic resistance has been attributed to CSCs [80,82-87], which subsequently leads to increased tumor growth, invasion, and relapse.”
BackgroundNatural products for combating multidrug resistance in cancer
Chen, T., Xiao, Z., Liu, X., Wang, T., Wang, Y., Ye, F., Su, J., Yao, X., Xiong, L., & Yang, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107099 · Cited by 130
Kuete, V., Sandjo, L. P., Ouete, J. L. N., Fouotsa, H., Wiench, B., & Efferth, T. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.08.018 · Cited by 116
Multidrug Resistance Through the Spectacle of P-Glycoprotein
Goda, K., Bacsó, Z., & Szabo, G. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166493 · Cited by 124
Hall, M. D., Brimacombe, K. R., Varonka, M. S., Pluchino, K. M., Monda, J. K., Li, J., Walsh, M. J., Boxer, M. B., Warren, T. H., Fales, H. M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006047 · Cited by 116
Self-citationGuo, C., Yu, H., Feng, B., Gao, W., Yan, M., Zhang, Z., Li, Y., & Liu, S. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.054 · Cited by 116
Doxorubicin Loaded pH-sensitive Micelle: Antitumoral Efficacy against Ovarian A2780/DOXR Tumor
Kim, D., Lee, E. S., Park, K., Kwon, I. C., & Bae, Y. H. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9603-6 · Cited by 116
Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review
Cornelison, R., Llaneza, D. C., & Landen, C. N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102171 · Cited by 130
“They are a diverse group of ATP-dependent efflux pumps containing 48 different family members with a common structural theme: a variable transmembrane domain and a conserved nucleotide binding domain [32,41].”
BackgroundXiao, W., Liu, L., Guo, X., Wang, Y., Zhao, J., & Zhou, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b04163 · Cited by 114
Sun, Y., Ma, W., Yang, Y., He, M., Li, A., Bai, L., Yu, B., & Yu, Z. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.04.005 · Cited by 122
Yang, K., Zhang, S., He, J., & Nie, Z. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101046 · Cited by 120
Cheng, L., Luo, S., Jin, C., Ma, H., Zhou, H., & Li, J. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.450 · Cited by 114
Wagner, C. C., Bauer, M., Karch, R., Feurstein, T., Kopp, S., Chiba, P., Kletter, K., Löscher, W., Müller, M., Zeitlinger, M. A., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063289 · Cited by 113
“A promising strategy to enhance drug penetration across the BBB and thereby overcome drug resistance is the administration of new-generation P-gp inhibitors, which were originally developed as an adjunctive therapy for drug-resistant cancers and are characterized by a high potency in the nanomolar range, lack of toxic…”
Highlights in Resistance Mechanism Pathways for Combination Therapy
Delou, J. M. D. A., Souza, A. S. O., Souza, L. C. D. M. E., & Borges, H. L. (2019) · Cells · doi:10.3390/cells8091013 · Cited by 126
“The development of reliable and validated methods for the adequate detection and quantification of ABC transporters is an ongoing challenge [17,19].”
InfluentialEckford, P. D. W., & Sharom, F. J. (2008) · Biochemistry · doi:10.1021/bi801409r · Cited by 115
Wang, Z., Yu, Y., Dai, W., Lu, J., Cui, J., Wu, H., Yuan, L., Zhang, H., Wang, X., Wang, J., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.031 · Cited by 116
“within cancer cells, leading to inadequate drug effects and poor prognosis [7,8].”
BackgroundŠtaud, F., Červený, L., & Čečková, M. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.716847 · Cited by 126
“In addition, MRPs can efflux various xenobiotics from cells and influence their pharmacokinetics (see Table 1) (Szakacs et al., 2006).”
BackgroundZhong, Y., Zhang, F., Sun, Z., Zhou, W., Li, Z., You, Q., Guo, Q., & Hu, R. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.21921 · Cited by 110
Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors
Dalvi, M. P., Wang, L., Zhong, R., Kollipara, R. K., Park, H., Bayo, J., Yenerall, P. M., Zhou, Y., Timmons, B. C., Rodriguez‐Canales, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.077 · Cited by 123
“Clinical trials using MDR inhibitors have been unsuccessful because of associated toxicity to normal tissues or lack of response due to collateral mechanisms of resistance (Bradshaw and Arceci, 1998; Szakács et al., 2006).”
BackgroundPape, V. F. S., Tóth, S., Füredi, A., Szebényi, K., Lovrics, A., Szabó, P. T., Wiese, M., & Szakács, G. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.078 · Cited by 123
Self-citationZhao, X., & Liu, P. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am505531e · Cited by 113
Epithelial Organic Cation Transporters Ensure pH-Dependent Drug Absorption in the Airway
Horváth, G., Schmid, N., Fragoso, M. A., Schmid, A., Conner, G. E., Salathe, M. A., & Wanner, A. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0230oc · Cited by 130
“Although their functions have largely been studied in the context of decreased intracellular concentrations of cytotoxic anti-cancer drugs (36), the basolateral transporters are likely involved in the transepithelial movements of aerosolized drugs previously absorbed into the airway epithelium.”
BackgroundAmjad, M. W., Amin, M. C. I. M., Katas, H., Butt, A. M., Kesharwani, P., & Iyer, A. K. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00827 · Cited by 112
Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy
Edelman, R., Assaraf, Y. G., Levitzky, I., Shahar, T., & Livney, Y. D. (2017) · Oncotarget · doi:10.18632/oncotarget.15363 · Cited by 111
Tetrandrine and cancer – An overview on the molecular approach
Bhagya, N., & Chandrashekar, K. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.116 · Cited by 114
Tsujimura, S., Saito, K., Nawata, M., Nakayamada, S., & Tanaka, Y. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.070821 · Cited by 111
Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents
El‐Nassan, H. B. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.031 · Cited by 120
Camptothecin Resistance in Cancer: Insights into the Molecular Mechanisms of a DNA-Damaging Drug
Beretta, G. L., Gatti, L., Perego, P., & Zaffaroni, N. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320120006 · Cited by 119
“Although the precise contribution of all identified transporters to clinical resistance to CPTs has not been clearly defined, preclinical studies have shown that the mechanisms leading to over-expression of ABC transporters in tumor cells may be multiple and may comprise both genetic and epigenetic alterations [49, 50…”
BackgroundIntelligent nanoparticles for advanced drug delivery in cancer treatment
Spencer, D. S., Puranik, A. S., & Peppas, N. A. (2015) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2014.12.003 · Cited by 124
“Multidrug resistance in cancer cells, a condition which can accompany metastatic cancer, is responsible for numerous cancer-related deaths and can render first line therapies ineffective [50].”
BackgroundRole of microRNAs in chemoresistance.
Magee, P., Shi, L., & Garofalo, M. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.11.32 · Cited by 70
“The mechanisms of such drug resistance mostly are as yet to be elucidated and the targets and pathways involved represent an area of intense investigation (2).”
BackgroundAntibody–Drug Conjugates for Cancer Therapy
Parslow, A. C., Parakh, S., Lee, F.-T., Gan, H. K., & Scott, A. M. (2016) · Biomedicines · doi:10.3390/biomedicines4030014 · Cited by 120
“Multidrug resistance (MDR) involves a family of adenosine triphosphate-binding cassette (ABC) energy-dependent transporters who play critical roles in the efflux of cytotoxic compounds from the cell [93,94].”
BackgroundMollaei, M., Hassan, Z. M., Khorshidi, F., & Langroudi, L. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101056 · Cited by 129
Zhong, Z., Vong, C. T., Chen, F., Tan, H., Zhang, C., Wang, N., Cui, L., Wang, Y., & Feng, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21876 · Cited by 118
“In fact, targeting a single pathway is hard to tackle chemoresistance due to the multifaceted MDR, thus overcoming MDR has been a major goal for cancer biologists by using novel and multiple strategies during the past 50 years.(83) Cancer immunotherapy could be a vital adjunct strategy to circumvent and overcome MDR,…”
BackgroundKuteykin‐Teplyakov, K. B., Luna‐Tortós, C., Ambroziak, K., & Löscher, W. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00801.x · Cited by 110
“However, vinblastine is wellknown to be a substrate for human Pgp (Silverman, 1999; Szakács et al., 2006), so that this cTR calculation would lead to a ‘false-negative’ result.”
BackgroundTrackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance
Zhang, Y., Zhang, C., Chen, J., Liu, L., Hu, M., Li, J., & Bi, H. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b07219 · Cited by 109
Magnetic nanoparticles for cancer therapy
Dürr, S., Janko, C., Lyer, S., Tripal, P., Schwarz, M. A., Zaloga, J., Tietze, R., & Alexiou, C. (2013) · Nanotechnology Reviews · doi:10.1515/ntrev-2013-0011 · Cited by 109
“, antibodies to ABC transporters) [88] .”
Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells
Türk, D., Hall, M. D., Chu, B. F., Ludwig, J. A., Fales, H. M., Gottesman, M. M., & Szakács, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2422 · Cited by 118
“Although several ABC transporters have been shown to transport anticancer drugs in vitro, P-glycoprotein (Pgp/MDR1/ABCB1) stands out by conferring the highest level of resistance to a vast array of drugs and because of its shown association with clinical multidrug resistance (MDR) and poor clinical outcome (1).”
BackgroundInfluentialSelf-citationHollow iron oxide nanoparticles as multidrug resistant drug delivery and imaging vehicles
Xing, R., Bhirde, A. A., Wang, S., Sun, X., Liu, G., Hou, Y., & Chen, X. S. (2012) · Nano Research · doi:10.1007/s12274-012-0275-5 · Cited by 110
“Multidrug resistance (MDR) is a huge problem encountered in cancer therapy [1].”
BackgroundStacy, A. E., Palanimuthu, D., Bernhardt, P. V., Kalinowski, D. S., Jansson, P. J., & Richardson, D. R. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01050 · Cited by 109
Novel Metal Polyphenol Framework for MR Imaging-Guided Photothermal Therapy
Zhao, G., Wu, H., Feng, R., Wang, D., Xu, P., Jiang, P., Kang, Y., Wang, H., Guo, Z. G., & Chen, Q. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b16222 · Cited by 109
Wang, J., Miller, D. D., & Li, W. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.12.001 · Cited by 114
Kuete, V., Sandjo, L. P., Djeussi, D. E., Zeino, M., Kwamou, G. M. N., Ngadjui, B. T., & Efferth, T. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0137-y · Cited by 111
“The overexpression of ABC transporters, particularly P-glycoproteins (P-gp) has been involved in multidrug resistance of cancer cells and subsequently the failure of cancer chemotherapy [1].”
BackgroundMuthoosamy, K., Abubakar, I. B., Bai, R. G., Loh, H., & Manickam, S. (2016) · Scientific Reports · doi:10.1038/srep32808 · Cited by 113
Chakraborty, C., Sharma, A. R., Sharma, G., Sarkar, B. K., & Lee, S.-S. (2018) · Oncotarget · doi:10.18632/oncotarget.24309 · Cited by 108
“Despite considerable success with ‘combination therapy’ in chemotherapy treatment programs, resistance to chemotherapeutic treatment has emerged as a challenge to effective treatment [56, 57].”
Background
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.